EVO756
Small molecule
Evidence outlook
Migraine: mid-stage studies underway, no completed readout
In Migraine, Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. Studies in other indications have read out; see the trials and Regulatory events below.
Also in development:Chronic Inducible Urticaria · Phase 2
Development in Atopic Dermatitis stopped (2026-09-08) after a negative readout. Source
Company guidance: data expected in 2027 (Evommune, 6 Aug 2026). “We have also initiated a Phase 2b trial of EVO756 in migraine prophylaxis in July 2026 and we expect to report initial results in 2027.” Source ↗
Company guidance: topline data expected 2H 2027 (Evommune, 12 Nov 2026). “Phase 2b Dose-Ranging Trial in Migraine Prophylaxis Top-line Data Expected in 2H 2027 © Evommune, Inc. BL = Baseline; CFB = change from baseline; MMD = monthly migraine days; MHD = monthly headache days; QoL = quality of life BL Adults with Refractory Migraine ≥6 Days/Month (N ≈ 330) Screening Enrollment W12 EVO756, 25mg BID EVO756, 50mg BID Placebo Randomized, Double-Blind, Placebo-Controlled Trial Primary Endpoint Mean CFB in MMD Key Secondary Endpoints ≥50%, ≥75% reduction in MMD CFB in MHDs CFB in monthly acute migraine medication use Exploratory Endpoints Patient subtyping Changes in biomarkers Change in migraine-specific QoL” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07616128 NCT07616128 · Migraine Registry: NCT07616128 | 2 | Mean change from baseline in the number of monthly migraine days (MMD) (Last month of the 12-week treatment period) 2027-10 | In progress: results expected 1 Oct 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Chronic Inducible Urticaria: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| EVO756: this drug | Phase 2 | Small molecule | MRGPRX2 | not yet graded | No reviewed efficacy summary in this indication | |
| Barzolvolimab | Phase 3 | Monoclonal antibody | KIT | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow EVO756 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
October 2027 (1)
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent